Recursion Pharmaceuticals Announces Dr. H. Perry Fell as the First Member of Business Advisory Panel
Recursion Pharmaceuticals, a biotech start-up in Salt Lake City today announced the formation of its Business Advisory Panel. The first appointment to the Advisory Panel is H. Perry Fell, MBA, Ph.D. Perry is a distinguished scientist and leader who most prominently co-founded Seattle Genetics (NASDAQ: SGEN) and served as its CEO from start-up through IPO.
Salt Lake City, UT, June 05, 2014 --(PR.com)-- Recursion Pharmaceuticals is pleased to announce the appointment of H. Perry Fell to its Business Advisory Panel. Dr. Fell is a well-regarded life science executive with decades of relevant experience. Dr. Dean Y. Li, CSO of Recursion and the Vice-Dean of Research at the University of Utah Health Sciences Center adds: “We are so pleased to have Perry Join us. Perry’s experience at Bristol-Myers Squibb, his insight to grab the opportunity to spin out its technology to build Seattle Genetics, and their pioneering efforts to develop drug-antibody conjugates provides us with a role model we hope to learn from and emulate. I am excited not only for what Recursion will do for the rare-disease drug-discovery space, but also what it will mean for Salt Lake City as we seek to grow one of the most innovative pharmaceutical companies in the world right here at the foot of the Wasatch.”
Dr. Fell, along with several others to be announced at a later date, will advise Recursion Pharmaceuticals on a wide range of topics including business strategy and business development.
H. Perry Fell, MBA, Ph.D. - Dr. Perry Fell is an experienced researcher who has had great success as a scientist-founder and scientist-CEO. Perry brings with him vast experience and wisdom in overcoming both scientific and business challenges in the life sciences. He was the Director of Molecular Immunology at Bristol-Myers Squibb Pharmaceutical Research Institute from 1989 to 1997. In 1997, he co-founded Seattle Genetics (NASDAQ: SGEN), and served as the CEO from start-up through IPO. At Seattle Genetics, Dr. Fell and his team pioneered the use of antibody-drug conjugates for the treatment of various cancers. He subsequently served as the Chairman of the Board of Seattle Genetics from 2002-2004. From 2004-2009, Perry was the Chairman, CEO, and President of NanoString Technologies (NASDAQ: NSTG). Perry is currently the Chairman of Prevencio, a company dedicated to bringing new diagnostics to the ER, cardiology clinics, and clinical laboratories.
About Recursion Pharmaceuticals - Recursion Pharmaceuticals, LLC, is a drug discovery company founded in 2013 based on technology developed at the University of Utah. Recursion uses a novel drug screening platform to efficiently reposition drugs to treat rare genetic diseases. The company’s focus on rare genetic diseases is much-needed, as there are more than 5,000 such conditions that together affect millions of Americans, and more than 95% of these diseases have no approved therapy. Recursion’s novel drug screening platform combines experimental biology and bioinformatics in a massively parallel system to quickly and efficiently identify treatments for multiple rare genetic diseases. The core of the approach revolves around high-throughput automated screening using high-content assays in human cells, which allows the near simultaneous modeling of hundreds of genetic diseases. Rich data from these assays is probed using advanced statistical and machine learning approaches, and the effects of thousands of known drugs and shelved drug candidates can be investigated efficiently to identify those holding the most promise for the treatment of any one rare genetic disease.
See www.recursionpharma.com for more information.
Contact: Recursion Pharmaceuticals, LLC.
Chris Gibson, CEO.
Phone (801) 587-1629
Email: chris.gibson@recursionpharma.com
Dr. Fell, along with several others to be announced at a later date, will advise Recursion Pharmaceuticals on a wide range of topics including business strategy and business development.
H. Perry Fell, MBA, Ph.D. - Dr. Perry Fell is an experienced researcher who has had great success as a scientist-founder and scientist-CEO. Perry brings with him vast experience and wisdom in overcoming both scientific and business challenges in the life sciences. He was the Director of Molecular Immunology at Bristol-Myers Squibb Pharmaceutical Research Institute from 1989 to 1997. In 1997, he co-founded Seattle Genetics (NASDAQ: SGEN), and served as the CEO from start-up through IPO. At Seattle Genetics, Dr. Fell and his team pioneered the use of antibody-drug conjugates for the treatment of various cancers. He subsequently served as the Chairman of the Board of Seattle Genetics from 2002-2004. From 2004-2009, Perry was the Chairman, CEO, and President of NanoString Technologies (NASDAQ: NSTG). Perry is currently the Chairman of Prevencio, a company dedicated to bringing new diagnostics to the ER, cardiology clinics, and clinical laboratories.
About Recursion Pharmaceuticals - Recursion Pharmaceuticals, LLC, is a drug discovery company founded in 2013 based on technology developed at the University of Utah. Recursion uses a novel drug screening platform to efficiently reposition drugs to treat rare genetic diseases. The company’s focus on rare genetic diseases is much-needed, as there are more than 5,000 such conditions that together affect millions of Americans, and more than 95% of these diseases have no approved therapy. Recursion’s novel drug screening platform combines experimental biology and bioinformatics in a massively parallel system to quickly and efficiently identify treatments for multiple rare genetic diseases. The core of the approach revolves around high-throughput automated screening using high-content assays in human cells, which allows the near simultaneous modeling of hundreds of genetic diseases. Rich data from these assays is probed using advanced statistical and machine learning approaches, and the effects of thousands of known drugs and shelved drug candidates can be investigated efficiently to identify those holding the most promise for the treatment of any one rare genetic disease.
See www.recursionpharma.com for more information.
Contact: Recursion Pharmaceuticals, LLC.
Chris Gibson, CEO.
Phone (801) 587-1629
Email: chris.gibson@recursionpharma.com
Contact
Recursion Pharmaceuticals
Chris Gibson
801-587-1629
www.recursionpharma.com
Chris Gibson
801-587-1629
www.recursionpharma.com
Contact
Categories